One recent study on lymphoma using irreversible electroporation combined with anti-PD1 and TLR3/9 agonists indicated a sound treatment response by reversing the immunosuppressive TME, including the reduction in MDSCs (65). This evidence concerns the gene TLR3 and lymphoma.